Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lorundrostat · MLS-101

Small molecule · developed by Mineralys Therapeutics

Phase 3 Most advanced trial

MLYS Developer

3 Registered trials

What is Lorundrostat?

Lorundrostat is an investigational small-molecule drug studied in Hypertension, Hypertension, Renal.

At a glance

Also known as: MLS-101
Drug type: Small molecule
Therapy area: Cardiovascular
Developer: Mineralys Therapeutics Inc. (MLYS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: KA8W5LDS6Z

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06153693	Phase 3	Hypertension	Completed	MLYS
NCT05968430	Phase 3	Hypertension	Active not recruiting	MLYS
NCT05001945	Phase 2	Hypertension, Renal	Completed	MLYS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HypertensionHypertension, Renal

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MLYS page.

Follow MLYS, the company behind Lorundrostat

See MLYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MLYS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z